About the
NeLM
|
Help & Support
|
Site Feedback
|
Update Newsletter Subscription
Homepage
Login
|
Register
Search the NeLM
Medicines A-Z
Find key information about medicines by name (prototype)
Browse by Categories:
BNF Category
|
Medical Specialty
|
National Health Service
|
Medicines Information
Browse by NeLM area:
Evidence
|
Other Library Updates
|
News
|
Health In Focus
|
Medicines A-Z
|
Communities
|
Useful Links
|
Formularies
BNF Category
1: Gastro-intestinal system
2: Cardiovascular system
3: Respiratory system
4: Central nervous system
5: Infections
6: Endocrine system
7: Obstetrics, gynaecology, and urinary-tract disorders
8: Malignant disease and immunosuppression
9: Nutrition and blood
10: Musculoskeletal and joint diseases
11: Eye
12: Ear, nose, and oropharynx
13: Skin
14: Immunological products and vaccines
15: Anaesthesia
Appendix 7
Appendix 8 Wound management products and elasticated garments
Non-BNF miscellaneous
Emergency treatment of poisoning
8.1 Cytotoxic drugs
8.2 Drugs affecting the immune response
8.3 Sex hormones and hormone antagonists in malignant disease
3755 library items
in 8: Malignant disease and immunosuppression
Filter results by:
Date Published
2012 (275)
2011 (713)
2010 (701)
2009 (651)
2008 (516)
More
NeLM
Area
News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies
Results filtered by:
Category
8: Malignant disease and immunosuppression (
remove
)
Sort by:
Least recent publication date
Most recent publication date
Title alphabetical A-Z
Title alphabetical Z-A
Source alphabetical A-Z
Source alphabetical Z-A
Display summary:
No
Yes
Results 1 - 10 of 3755
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next
1.
Updated national IV monograph on Natalizumab
Source:
Medusa
,
Date published:
16/05/2012
Category:
8.2.4 Other immunomodulating drugs
|
Drug Administration
NeLM
Area:
News
Link- registration required
2.
FDA Drug Safety Communication: Revised recommendations for cardiac monitoring and use of fingolimod (Gilenya®)
Source:
FDA
,
Date published:
15/05/2012
Category:
8.2.4 Other immunomodulating drugs
|
Adverse Drug Reactions
|
Food &Drug Administration (FDA)
|
Multiple sclerosis
NeLM
Area:
News
Link
3.
Outcome at 5 years following response to rituximab therapy in children and adults with ITP
Source:
Blood
,
Date published:
15/05/2012
Category:
8.2.3 Anti-lymphocyte monoclonal antibodies
|
Haematology
NeLM
Area:
News
Link (abstract)
4.
Funding oncology clinical trials: are cooperative group trials sustainable?
Source:
Journal of Clinical Oncology
,
Date published:
15/05/2012
Category:
8.1 Cytotoxic drugs
|
Pharmaceutical Industry
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link
5.
SMC does not recommend ipilimumab (Yervoy®) for advanced melanoma
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: skin
|
Drug reviews
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
6.
SMC accepts everolimus (Afinitor®) for use in the treatment of neuroendocrine tumours of pancreatic origin (pNET)
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Drug reviews
|
Oncology
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
7.
SMC does not recommend bevacizumab (Avastin®) for first-line treatment of metastatic breast cancer
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: breast
|
Drug reviews
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
8.
Generic immunosuppression: deciphering the message our patients are receiving
Source:
Annals of Pharmacotherapy
,
Date published:
15/05/2012
Category:
8.2 Drugs affecting the immune response
|
Generic prescribing
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link
9.
London Cancer New Drugs Group Rapid Review: Bortezomib as first line induction prior to melphalan and ASCT in untreated symptomatic multiple myeloma patients
Source:
London Cancer New Drugs Group
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: other
|
Drug reviews
NeLM
Area:
Evidence
>
Drug Specific Reviews
LCNDG_Bortezomib_1st_line
10.
New national IV monograph on Ofatumumab
Source:
Medusa
,
Date published:
15/05/2012
Category:
8.2.3 Anti-lymphocyte monoclonal antibodies
|
Drug Administration
NeLM
Area:
News
Link- registration required
Results 1 - 10 of 3755
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next